Ulcerogenesis: Integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages

  Peura, David A ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DUODENUM ULCER; HELICOBACTER PYLORI; HUMAN; INTESTINE MUCOSA; PRIORITY JOURNAL; STOMACH ACID SECRETION; ULCEROGENESIS;

DUODENAL ULCER; DUODENUM; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA;

EID: 0030909559     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease: Pathophysiology/diagnosis/ management, 5th ed, vol 1. Philadelphia: WB Saunders, 1993:580-679.
2. Freston JW. Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin North Am 1990;19:121-40.
3. Yamada T, Ahnen D, Alpers DH, et al. Helicobacler pylori in peptic ulcer disease. JAMA 1994;272:65-9.
4. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Ailment Pharmacol Ther 1995;9(suppl 2):59-69.
5. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333:984-91.
6. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977-81.
7. Moss S, Calam J. Helicobacter pylori and peptic ulcers: The present position. Gut 1992;33:289-92.
8. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without antiacid treatment: Randomised, controlled trial. Lancet 1994;343:508-10.
9. Sipponen P. Chronic gastritis and ulcer risk. Scand J Gastroenterol 1990;25:193-6.
10. Peterson W, Barnett CC, Evans DI, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: The role of Helicobacter pylori. Am J Gastroenterol 1993;88:2038-43.
11. El-Omar EM, Penman ID, Ardill JES, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-91.
12. Isenberg JI, McQuaid KR, Laine L, et al. Acid-peptic disorders. In: Yamada T, ed. Textbook of gastroenterology. Philadelphia: JB Lippincott, 1995:1347-430.
13. Reid J, Taylor TV, Holt S, et al. Benign gastric ulceration in pernicious anemia. Dig Dis Sci 1980;25:148-9.
14. Isenberg JI, Spector H, Hootkin LA, et al. An apparent exception to Schwartz's dictum, "no acid-no ulcer." N Engl J Med 1971;286:620.
15. Feldman M. Gastric secretion in health and disease. In: Sleisenger MH, Fortran JS, eds. Gastrointestinal disease. Philadelphia: WB Saunders, 1989:713-34.
16. Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987;28:1120-7.
17. Walsh JH, Richardson CT, Fortran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 1975;55:462-8.
18. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-27.
19. Florent C. Progress with proton pump inhibitors in acid peptic disease: Treatment of duodenal and gastric ulcer. Clin Ther 1993;15(suppl B):14-21.
20. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(suppl 1):13-24.
21. Maton PN. Omeprazole. N Engl J Med 1991;324:965-75.
22. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
23. 2-receptor antagonists alone completely block food stimulated acidity? Eur J Gastroenterol Hepatol 1991;3:533-7.
24. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992;116:705-8.
25. Penston JG. Helicobacter pylori eradication: Understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-89.
26. Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8:359-68.
27. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.
28. Sipponen P, Varis K, Fraki O, et al. Cumulative 10 year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 1990;25:866-973.
29. Sarosiek J, Marshall BJ, Peura DA, et al. Gastroduodenal mucus gel thickness in patients with Helicobacter pylori: A method for assessment in biopsy specimens. Am J Gastroenterol 1991;86:729-34.
30. Sarosiek J, Slomiany A, Slomiany BL. Evidence for weakening of gastric mucus integrity by Campylobacter pylori. Scand J Gastroenterol 1988;23:585-90.
31. Rauws EAJ, Langenberg W, Houthoff HJ, et al. Campylobacter pyloridis-associated chronic active antral gastritis: A prospective study in prevalence and the effects of anti-bacterial and anti-ulcer treatment. Gastroenterology 1988;94:33-40.
32. Sipponen P, Seppala K, Aarynen M, et al. Chronic gastritis and gastroduodenal ulcer: A case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut 1989;30:922-9.
33. Malfertheimer P, Boce G. Helicobacter pylori and the pathogenesis of duodenal ulcer disease. Eur J Gastroenterol Hepatol 1993;5:1-8.
34. Ernst PB, Jin Y, Reyes VE, et al. The role of the local immune response in the pathogenesis of peptic ulcer formation. Scand J Gastroenterol 1994;29(suppl 205):22-8.
35. Triebling AT, Korsten MA, Diugosz JW, et al. Severity of Helicobacter-induced gastric injury correlates with gastric juice ammonia. Dig Dis Sci 1991;36:1089-96.
36. Dixon MF. Pathophysiology of Helicobacter pylori infection. Scand J Gastroenterol 1994;29(suppl 201):7-10.
37. Crabtree JE, Shallcross TM, Heatley RV, et al. Mucosal tumor necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori-associated gastritis. Gut 1991;32:1473-7.
38. Crabtree JE, Farmery SM, Lindley IJD, et al. CagA/cytotxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994;47:945-50.
39. Noach LA, Bosma B, Jansen J, et al. Mucosal tumour necrosis factor-α, interleukin-1b, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425-9.
40. Khulusi S, Badve S, Patel P, et al. Pathogenesis of gastric metaplasia of the human duodenum: Role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 1996;110:452-8.
41. Wyatt JI, Rathbone BJ, Sobala GM, et al. Gastric epithelium in the duodenum: Its association with Helicobacter pylori and inflammation. J Clin Pathol 1990;43:981-6.
42. Carrick J, Lee A, Hazell S, et al. Campylobacter pylori, duodenal ulcer, and gastric metaplasia: Possible role of functional heterotopic tissue in ulcerogenesis. Gut 1989;30:790-7.
43. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993;90:5791-5.
44. Figura N, Guglielmetti P, Rossolini A, et al. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol 1989; 27:225-6.
45. Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991;338:332-5.
46. Rautelin H, Blomberg B, Fredlund H, et al. Incidence of Helicobacter pylori strains activating neutrophils in patients with peptic ulcer disease. Gut 1993;34:599-603.
47. Sumii M, Sumii K, Tari A, et al. Expression of antral gastrin and somatostatin mRNA in Helicobacter pylori-infected subjects. Am J Gastroenlerol 1994;89:1515-9.
48. Odum L, Petersen HJD, Andersen IB, et al. Gastrin and somatostatin in Helicobacter pylori-infected antral mucosa. Gut 1994;35:615-8.
49. Queiroz DM, Moura SB, Mendes EN, et al. Effect of Helicobacter pylori eradication on G-cell and D-cell density in children. Lancet 1994;343:1191-3.
50. Queiroz DMM, Mendes EN, Rocha GA, et al. Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993;28:858-64.
51. El-Omar E, Penman I, Dorrian CA, et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two-thirds in patients with duodenal ulcer. Gut 1993;34:1060-5.
52. McColl KEL, Fullarton GM, Chittajallu R, et al. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 1991;26:339-46.
53. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
54. Logan RPH, Bardhan KD, Celestin LR, et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: A randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995;9:417-23.
55. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The Mach 1 study: Optimal one-week treatment for H. pylori defined? Gut 1995;39(suppl 1):A4.